Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Apr 15, 2009 (Vol. 29, No. 8)

Novel Systems Zero In on the $100 Genome

Technology under Development Is Being Counted on to Provide Rapid and Affordable Sequencing

  • Sequencing-by-Synthesis Chemistry

    Click Image To Enlarge +
    DNA Sequence Analysis Software

    “We have obtained worldwide licensing for our exclusive technology,” commented Jerzy Olejnik, Ph.D., vp for process R&D at Intelligent Bio-Systems, referring to the sequencing-by-synthesis chemistry developed at Columbia University. The basis of the technology is the binding of PCR-amplified fragments of DNA to a solid surface, and then building of a complementary sequence using polymerase and specially modified reversible terminator fluorescent nucleotides in four colors. The reagents are unique and low-cost, as is the instrument itself, driving down the overall cost per base, said Dr. Olejnik.

    “The system and sample-preparation kits associated with it allows high accuracy and sensitivity of sequencing as well as opening the possibility of specialized applications such as digital gene-expression profiling and methylation profiling,” Dr. Olejnik continued.

    The instrumentation, which is referred to as PinPoint, is outfitted with a high-speed imaging system and an ordered array-based disposable chip.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »